Loading clinical trials...

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Clinical Trials | Clareo Health

RECRUITINGPHASE1

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758•Amgen

View on ClinicalTrials.gov

Summary

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participant has provided informed consent before initiation of any study-specific activities/procedures.
•2. Participants ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
•3. Participants with histologically or cytologically confirmed ES-SCLC that has progressed or recurred following at least 1 line of anti-cancer therapy for ES-SCLC.
•4. Participants must have at least 1 measurable lesion as defined by RECIST 1.1 within 21-day screening period, not previously irradiated.
•5. Participants must have adequate organ function (hematological, coagulation, cardiac, pulmonary, kidney, and liver).
•6. Participants must submit a fresh tumor biopsy at screening unless a new biopsy cannot be performed safely or is infeasible. Participants who cannot provide fresh tissue may provide archival tissue that was collected after last anticancer therapy.
•3. Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy (including tarlatamab).
•4. Prior interleukin (IL)-2, IL-7 or IL-15 targeted therapy.
•5. Baseline (at rest) requirement of supplemental oxygen.

Exclusion Criteria

•1. Symptomatic central nervous system (CNS) metastases.

Locations (17)

University of Southern California, Norris Comprehensive Cancer Center

Los Angeles, California, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University

Atlanta, Georgia, United States

Norton Cancer Institute - Downtown

Louisville, Kentucky, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Siteman Cancer Center

St Louis, Missouri, United States

Sidney Kimmel Cancer Center

Philadelphia, Pennsylvania, United States

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Avera Cancer Institute

Sioux Falls, South Dakota, United States

Baptist Cancer Center

Memphis, Tennessee, United States

Key Dates

Start Date

September 16, 2025

Primary Completion Date

March 18, 2028

Completion Date

January 18, 2031

Last Updated

February 20, 2026

Enrollment

380

ESTIMATED participants

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

Tarlatamab

DRUG

AB248

DRUG

Contacts

Amgen Call Center

CONTACT

866-572-6436 medinfo@amgen.com

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

NCT05468489

Extensive Stage Small Cell Lung Cancer

View study

COMPLETED

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

NCT05055999

Extensive Stage Small Cell Lung Cancer

View study

COMPLETEDNA

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Inclusion Criteria

Exclusion Criteria

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors